ArticleThe lancet. HIV2016

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Ian McGowan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.